Drug Search Results
More Filters [+]

INB-01

Alternative Names: INB-01, INB01
Latest Update: 2023-03-23
Latest Update Note: Clinical Trial Update

Product Description

INB-01 technology is designed to deliver pharmaceutical compounds as a liquid at room temperature, which becomes a gel instantaneously in the nasal cavity. The novel technology has been successfully utilized with both water-soluble and insoluble compounds and extracts. (Sourced from: https://ir.atai.life/news-releases/news-release-details/atai-life-sciences-announces-initiation-phase-1-proof-concept)

Mechanisms of Action: Device

Novel Mechanism: No

Modality: Device

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: ATAI Life Sciences
Company Location: NEW YORK NY 10014
Company CEO: Florian Brand
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for INB-01

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 0: Central Nervous System

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ACTRN12622001122741

N/A

Terminated

Healthy Volunteers

2022-12-09

Recent News Events